FDA will conduct more review of Eli Lilly's Alzheimer's drug donanemab - The Washington Post - The Washington Post

[news]

[news]

1. FDA will conduct more review of Eli Lilly's Alzheimer's drug donanemab - The Washington Post The Washington Post
2. U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab | Eli Lilly and Company Investors | Eli Lilly and Company
3. F.D.A. Delays Action on Closely Watched Alzheimer's Drug The New York Times
4. Eli Lilly's donanemab Alzheimer's drug delayed by FDA USA TODAY
5. Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting The Wall Street Journal

More...